GB0316139D0 - Use of fluoroquinolone antibiotics for the treatment of plague - Google Patents

Use of fluoroquinolone antibiotics for the treatment of plague

Info

Publication number
GB0316139D0
GB0316139D0 GBGB0316139.5A GB0316139A GB0316139D0 GB 0316139 D0 GB0316139 D0 GB 0316139D0 GB 0316139 A GB0316139 A GB 0316139A GB 0316139 D0 GB0316139 D0 GB 0316139D0
Authority
GB
United Kingdom
Prior art keywords
plague
treatment
fluoroquinolone antibiotics
fluoroquinolone
antibiotics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB0316139.5A
Other versions
GB2403653A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UK Secretary of State for Defence
Original Assignee
UK Secretary of State for Defence
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UK Secretary of State for Defence filed Critical UK Secretary of State for Defence
Priority to GB0316139A priority Critical patent/GB2403653A/en
Publication of GB0316139D0 publication Critical patent/GB0316139D0/en
Publication of GB2403653A publication Critical patent/GB2403653A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB0316139A 2003-07-10 2003-07-10 Use of fluoroquinone antibiotics for the treatment of plague Withdrawn GB2403653A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0316139A GB2403653A (en) 2003-07-10 2003-07-10 Use of fluoroquinone antibiotics for the treatment of plague

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0316139A GB2403653A (en) 2003-07-10 2003-07-10 Use of fluoroquinone antibiotics for the treatment of plague

Publications (2)

Publication Number Publication Date
GB0316139D0 true GB0316139D0 (en) 2003-08-13
GB2403653A GB2403653A (en) 2005-01-12

Family

ID=27741917

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0316139A Withdrawn GB2403653A (en) 2003-07-10 2003-07-10 Use of fluoroquinone antibiotics for the treatment of plague

Country Status (1)

Country Link
GB (1) GB2403653A (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716830B2 (en) * 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
AU2001280091A1 (en) * 2000-08-01 2002-02-13 Wockhardt Limited Inhibitors of cellular efflux pumps of microbes
US6413969B1 (en) * 2000-09-13 2002-07-02 Bristol-Myers Squibb Company Gatifloxacin pentahydrate
US20040014750A1 (en) * 2001-12-13 2004-01-22 Michaelis Arthur F. Metal complexes and formulations of rifamycin analogues and uses thereof
US7078399B2 (en) * 2001-12-13 2006-07-18 Activbiotics, Inc. Sulfhydryl rifamycins and uses thereof

Also Published As

Publication number Publication date
GB2403653A (en) 2005-01-12

Similar Documents

Publication Publication Date Title
ZA200504558B (en) Compounds for the treatment of metabolic disorders
EP1635813A4 (en) Combination therapy for the treatment of dyslipidemia
EP1638508A4 (en) Shunt for the treatment of glaucoma
HUS2200036I1 (en) Use of dihydroimidazolones for the treatment of dogs
ZA200305691B (en) The use of substituted azetidione compounds for the treatment of sitosterolemia
IL173655A0 (en) Novel use of quinolone antibiotics
GB0329874D0 (en) Compounds useful for the treatment of diseases
GB0305150D0 (en) Use of therapeutic compounds
AU2003290059A8 (en) Use of cd137 antagonists for the treatment of tumors
IL175412A0 (en) Use of specific histones for the treatment of parasitic diseases
IL160143A0 (en) Novel imidazopyridine compounds with therapeutic effect
EP1626692A4 (en) Compounds for the treatment of flaviviridae infections
PL371524A1 (en) Combination therapy for the treatment of bacterial infections
EP1827449A4 (en) The use of novel antibacterial compounds
EP1622615A4 (en) Naphthyridine integrase inhibitors
AU2003258983A8 (en) Combinations for the treatment of fungal infections
IL172101A0 (en) Use of indazole derivatives for the treatment of neuropathic pain
GB0316139D0 (en) Use of fluoroquinolone antibiotics for the treatment of plague
HK1087027A1 (en) Use of 2H-Ä1, 3Ü-oxazinoÄ3,2-AÜindole derivatives for the treatment of neuropathic pain
GB0307262D0 (en) Use of fluoroquinolone antibiotics for the treatment of q fever
NO20042542L (en) Use of ascomycin for the treatment of blepharitis
GB0224232D0 (en) Use of fluoroquinolone antibodies for the treatment of anthrax
IL175611A0 (en) Combinations for the treatment of proliferative diseases
GB0317128D0 (en) Use of antitumoral compounds
GB0325957D0 (en) The treatment of pain

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)